secwatch.observer — SEC 8-K summary
======================================

Issuer:     COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK:        0001267565
Form:       8-K
Filed at:   2024-05-24T23:59:59+00:00
Accession:  0001104659-24-065119
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Collegium appoints Michael Heffernan interim CEO with base salary $291,666; Ciaffoni separation agreed
--------------------------------------------------------------------------------

- Michael Heffernan appointed Interim President and CEO effective May 24, 2024; annual base salary $291,666 (one-third of prior CEO).
- Heffernan's employment is at-will; Board may terminate at any time or extend by mutual agreement.
- Separation and Release Agreement with departing CEO Joseph Ciaffoni grants severance per employment agreement for termination without cause.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267565/000110465924065119/0001104659-24-065119-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267565/000110465924065119/tm2415470d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-065119

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer